A Phase 3 study of the Roche therapy Gazyva (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma failed to meet its primary endpoint, even though two previous studies of the same drug in different blood cancers succeeded.
Bayer AG, whose name is usually associated with aspirin, has signaled its intention to deepen its commitment to crop science by raising its takeover bid for Monsanto Inc to $125 per share. The move values the company at $64 billion.
Cell Medica Ltd has completed another stage of its strategy for developing immunotherapies for solid tumours with the acquisition of Delenex Therapeutics AG, an antibody specialist based in Switzer
GW Pharmaceuticals Plc has raised gross proceeds of $252 million on the US Nasdaq market with the issue of 2.8 million American Depositary Shares (ADSs) to investors at a price of $90 per ADS.
The US biotech, Medivation Inc, has been successful at buying in new medicines for further development, but will selling itself be its most successful deal?
TiGenix NV has decided to withdraw ChondroCelect, its autologous product for knee repair, from the market due to lack of sales. The product was approved for marketing in 2009, but has not been reimbursed in ‘key European countries,’ the company said on 5 July.
A new UK medical device company with technology that aims to improve current methods of ablating tissue in tumours has been launched with seed funding of £500,000. Ablatus Therapeutics Ltd is a spin out of the Norfolk & Norwich University Hospitals NHS Foundation Trust.
Mesoblast Ltd is to do an early interim analysis of a Phase 3 trial of its cell therapy for heart failure in order to take a strategic view of the programme’s future. The analysis will take place in the first quarter of 2017, the Australian company announced on 1 July.
Nicox SA is undertaking another strategic reorganisation with plans to spin out its portfolio of marketed ophthalmology products in Europe into a new company in which it will have a minority stake. It will keep a R&D portfolio that includes two products in registration in the US.
Milan, Italy-based Dianax has received a €2 million European Union grant to support development of a portable diagnostic for the prevention and monitoring of diabetes. The device is designed to provide measurements of glycated haemoglobin.